close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Oxurion NV

< Previous 1 2 Next >
News headline image
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Announces Results of the Extraordinary Shareholders’ Meeting of 22 May 2023
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion to Participate in Upcoming Conferences
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Publishes 2022 Annual Report
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
From Oxurion NV
Via GlobeNewswire
News headline image
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Receives Transparency Notification from Negma Group
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Receives Transparency Notification from Negma Group
From Oxurion NV
Via GlobeNewswire
News headline image
Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding
From Oxurion NV
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today